[±Ù°Å±â¹Ý ÀÓ»óÁú¹® ´äº¯]
°£¾ÏȯÀÚ¿¡°Ô ADI-PEG 20 ´Üµ¶Åõ¿© È¿°ú ¿¬±¸ : Phase III randomized study
ÀÓ»óÁú¹®
|
ÁøÇàµÈ °£¼¼Æ÷¾Ï(Hepatocellular carcinoma, HCC) ȯÀÚ¿¡°Ô ADI-PEG 20 ´ÜÀÏ¿ä¹ýÀº »ýÁ¸±â°£(Overall Survival, OS) Çâ»ó¿¡ È¿°ú°¡ ÀÖ½À´Ï±î?
|
±Ù°Å±â¹Ý ´äº¯
|
ADI-PEG 20 ´ÜÀÏ¿ä¹ý¿¡¼ OS Áß¾Ó°ªÀº 7.8°³¿ùÀ̾ú°í ÇÁ¶ó¼¼º¸¸¦ Åõ¿©ÇÑ ±×·ìÀº 7.4°³¿ù·Î ADI-PEG 20 ´ÜÀÏ¿ä¹ýÀÌ OS¿¡ È¿°ú°¡ ÀÖÀ½À» ÀÔÁõÇÏÁö ¸øÇß½À´Ï´Ù.
|
¼ÁöÁ¤º¸
|
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma (2018). Ann Oncol. 2018 Jun 1;29(6):1402-1408.
Doi: 10.1093/annonc/mdy101.
|
¿¬±¸¸ñÀû
|
ÁøÇàµÈ °£¼¼Æ÷¾ÏȯÀÚ¿¡°Ô ¸ÅÁÖ ADI-PEG 20(18 mg/m2 versus placebo intramuscular injection weekly) Ä¡·áÈ¿°ú
|
¿¬±¸¼³°è
|
Phase III randomized clinical trial study
-NCT 01287585 µî·ÏµÊ : www.clinicaltrials.gov
-Multiinstitutional, randomized, placebo-controlled phase III clinical trial
|
¿¬±¸´ë»ó
|
18¼¼ ÀÌ»óÀÇ ±¹¼ÒÀûÀ¸·Î ÁøÇàµÈ HCC ȯÀÚ 635¸í
Eligible patients were randomized (2 : 1) to receive either weekly ADI-PEG 20 18 mg/m2 or placebo intramuscularly (i.m.) in a double-blinded fashion, with best supportive care.
|
½ÃÇ豺 ÁßÀç
|
ADI-PEG 20 monotherapy (18 mg/m2), n=424
|
´ëÁ¶±º ÁßÀç
|
placebo intramuscularly (i.m.), n=211
|
Æò°¡ÁöÇ¥
|
-ÁÖ¿ä Æò°¡ÁöÇ¥ : »ýÁ¸(Overall Survival, OS)
-2Â÷ Æò°¡ÁöÇ¥ : ¾ÈÀü¼º(safety)°ú ³»¾à¼º(tolerability
NCI CTCAE (Common Terminology Criteria for CTCAE) V.4.02À» ¹ÙÅÁÀ¸·Î, ¹ÝÀÀ·ü, ¹«ÁøÇà»ýÁ¸ (PFS), ¹× ÁøÇà½Ã°£(TtP)
|
ÁÖ¿ä°á°ú
|
»ýÁ¸·ü ºñ±³°á°ú : 7.8°³¿ù ADI-PEG 20 ±×·ì vs. 7.4°³¿ù ÇÁ¶ó¼¼º¸ ±×·ì[hazard ratio = 1.022 (95% CI, 0.847–1.233), P= 0.884]. PFS Áß¾Ó°ª : ¾çÂÊ µ¿ÀÏÇÏ°Ô 2.6 °³¿ù[hazard ratio = 1.175 (95% CI, 0.964–1.432), P = 0.075].
|
±Ù°Å¼öÁØ
|
High
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2015. Medical Research Information Center (MedRIC) Editors
|